Analysis | Metabolite Name | Measured Value | Units | Cell Type | Stimulation |
---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 13400000 | Peak area | PAK | Untreated |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 14100000 | Peak area | BS4 | TNF-alpha |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 15900000 | Peak area | PAK | IL-17A |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 16400000 | Peak area | PAK | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 17200000 | Peak area | BS4 | IL-17A |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 17400000 | Peak area | PAK | TNF-alpha |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 17500000 | Peak area | BS4 | IFN-G |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 18200000 | Peak area | BS4 | Untreated |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 19300000 | Peak area | BS4 | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 20100000 | Peak area | PAK | IFN-G |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 21600000 | Peak area | HAHA | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 21800000 | Peak area | HAHA | IFN-G |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 23100000 | Peak area | HAHA | IL-17A |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 23300000 | Peak area | HAHA | TNF-alpha |
Reversed phase NEGATIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M-H)- | 28600000 | Peak area | HAHA | Untreated |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3115473 | Peak area | PAK | Untreated |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3383523 | Peak area | PAK | TNF-alpha |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3402563 | Peak area | PAK | IL-17A |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3402904 | Peak area | BS4 | TNF-alpha |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3441154 | Peak area | HAHA | IL-17A |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3540772 | Peak area | BS4 | IL-17A |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3586786 | Peak area | HAHA | Untreated |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3650429 | Peak area | HAHA | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3659285 | Peak area | HAHA | TNF-alpha |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3763277 | Peak area | PAK | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3768408 | Peak area | BS4 | IFN-G |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3892448 | Peak area | HAHA | IFN-G |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 3942215 | Peak area | PAK | IFN-G |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 4032471 | Peak area | BS4 | Untreated |
Reversed phase POSITIVE ION MODE | 5-OXOPROLINE (CAS# 4042-36-8); (M+H)+ | 4310134 | Peak area | BS4 | TNF-alpha+IL-17A |